ArticleCureus2026
Dipeptidyl Peptidase-4 (DPP-4) Inhibitors Versus Glucagon-Like Peptide-1 (GLP-1) Receptor Agonists Following Orthopedic Shoulder Surgery: A Comparative Analysis.
Article in Cureus, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundDiabetes mellitus is an independent risk factor for complications following orthopedic shoulder procedures. Dipeptidyl peptidase-4 (DPP-4) inhibitors and glucagon-like peptide-1 (GLP-1) receptor agonists are effective agents that manage type 2 diabetes, but their differential effects on perioperative and long-term shoulder outcomes remain unclear.
methodsWe conducted a retrospective cohort study using the TriNetX Research Network, identifying adults (≥18 years) with type 2 diabetes who underwent orthopedic shoulder procedures and were prescribed either a DPP-4 inhibitor or a GLP-1 receptor agonist. Propensity score matching was performed (1:1), adjusting for demographics, comorbidities, and procedure type, yielding 632 patients per cohort. Outcomes included rates of reoperation at one and two years postoperatively and postoperative opioid use.
resultsAt one- and two-year follow-up, rates of reoperation were similar between cohorts. DPP-4 users had significantly higher early postoperative opioid use compared with GLP-1 users (RR: 1.754; 95% CI: 1.440-2.137; p < 0.001), whereas prolonged and chronic postoperative opioid use were similar between cohorts.
conclusionIn patients with type 2 diabetes undergoing orthopedic shoulder procedures, DPP-4 inhibitors and GLP-1 receptor agonists demonstrated comparable long-term surgical outcomes, including reoperation rates at one and two years postoperatively. However, early postoperative opioid use was significantly higher among DPP-4 users, while prolonged and chronic opioid utilization were similar between cohorts. These findings support the perioperative safety of both incretin-based therapies and suggest that GLP-1 receptor agonists may confer additional benefit through potential central pain-modulating effects that reduce early postoperative opioid requirements.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.